Kane Biotech Inc. (the "Company", "Kane Biotech" or "Kane") announces today that BioStem Technologies Inc. ("BioStem"), has recently signed a Letter of Intent to acquire commercial stage products and ...
BioStem made the announcement on November 20, 2024. The company indicated that the acquisition of revyve TM Antimicrobial Wound Gel reflects BioStem’s continued commitment to building a diverse ...
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyveTM from ProgenaCare Global WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc ...
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc ... including exclusive US distribution rights for Kane’s revyve TM Antimicrobial Wound Gel. BioStem made the announcement ...
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V ... including exclusive US distribution rights for Kane’s revyveTM Antimicrobial Wound Gel. BioStem made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback